{
  "id": 3649220,
  "title": "Daewoong Secures U.S. Patent for Ionizable Lipid",
  "url": "https://urgent.news/2026/08/27/daewoong-secures-u-s-patent-for-ionizable-lipid",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-27T03:02:16.000Z",
  "source": {
    "name": "BusinessKorea",
    "slug": "businesskorea",
    "url": "https://www.businesskorea.co.kr/news/articleView.html?idxno=275617"
  },
  "original_language": "en",
  "account": "On August 27, Daewoong Pharmaceutical received confirmation from the U.S. Patent and Trademark Office (USPTO) that its patent application for ionizable lipid technology had been granted. This technology is integral to Daewoong's \"eTurna\" lipid nanoparticle (LNP) delivery platform, which the company acquired from U.S. biotech firm Turn Biotechnologies. The patent covers the use of ionizable lipid structures within LNPs, which are crucial for safely delivering therapeutic nucleic acid materials, such as mRNA, to targeted cells without causing harm. mRNA is notoriously unstable in the body, and effective delivery technology is thus vital for the success of mRNA-based treatments. Daewoong's acquisition of Turn Bio's assets, including its cell reprogramming intellectual property, positions the company at the forefront of mRNA therapeutics. The company's ERA (Epigenetic Reprogramming of Aging) platform uses partial reprogramming technology to rejuvenate aged cells while maintaining their original identity. This technology has shown promising results in enhancing collagen VII expression and cell proliferation, while reducing aging markers and improving the functionality of immune cells like T cells. This progress, according to Daewoong's CEO Park Sung-soo, marks a significant milestone in reinforcing the company's competitive edge in the global mRNA therapeutics market. With the global reverse-aging therapeutics market anticipated to reach approximately $9.3 billion by 2035, Daewoong aims to leverage its unique original technology and robust R&D capabilities to develop groundbreaking reverse-aging drugs leading the global market.",
  "summary": "Daewoong Pharmaceutical said on Aug. 27 that the U.S. Patent and Trademark Office (USPTO) had notified the company of its decision to grant a patent for ionizable lipid-related technology, a core original technology of the lipid nanoparticle (LNP) delivery platform “eTurna,” which it acquired from U",
  "key_points": [
    "Daewoong Pharmaceutical receives USPTO confirmation for ionizable lipid patent on August 27.",
    "Patent covers ionizable lipid structures in eTurna LNP delivery platform.",
    "Acquisition of Turn Biotechnologies assets strengthens Daewoong's mRNA therapeutics position."
  ],
  "editors_take": "The patent grant strengthens Daewoong's position in the global mRNA therapeutics market by protecting its ionizable lipid technology, a crucial component of its lipid nanoparticle delivery platform.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}